Portfolio
Gabapentin and Women’s Health: Post-menopausal Hot Flashes
Xenolev – CR™
Gabapentin-GR™
Nanoparticle-based products
Gabapentin and Women’s Health: Post-Menopausal Hot Flashes
Many millions of women, worldwide, are seeking a safe and effective alternative to hormone replacement therapy (HRT) to treat vasomotor symptoms (VMS), such as hot flashes, sweating, and sleep disturbances associated with the menopause. HRT, the conventional treatment, has been linked to serious risks of cancer, stroke, and heart disease, and the World Health Organization has designated HRT as “carcinogenic”.
Gabapentin is a non-hormonal drug demonstrated to be safe and clinically effective in menopausal hot flashes and other, related conditions. Gabapentin does not act on the same organs, tissues and receptors as estrogen but instead is believed to act directly on the vasomotor center in the brain to normalize and stabilize vasomotor function.
PharmaNova owns the exclusive worldwide rights to the use and commercialization of gabapentin for the treatment of hot flashes and to certain other vasomotor conditions including the drug treatment of certain cancers.
Xenolev-CR™, is a unique modified release formulation of gabapentin, in development by PharmaNova for the treatment of menopausal hot flashes, for Europe (EU) and the Rest of the World (RoW), outside of the USA.
“Gabapentin-GR” is a proprietary formulation of gabapentin being developed for the United States, by Depomed Inc., (NASDAQ: DEPO; www.depomedinc.com) under sub-license from PharmaNova, for treatment of menopausal hot flashes.
These two products will provide safe and clinically proven non-hormonal prescription products that will address an important medical need, providing women around the world with a real choice in treatment, securing a significant market share around the world.
Nanoparticle based Products
PharmaNova has developed numerous candidate products based on its proprietary Precision Novasperse™ Technology in the fields of oncology and epilepsy. We also have nanoparticle projects in the field of anti-infective medications. These projects are currently in pre-clinical development and poised for partnering for further clinical development and out-licensing. Examples are:
NanopaxelTM is a Cremaphor-free nanoparticle formulation of the cancer chemotherapeutic paclitaxel.
NanocarbezineTM is a unique injectable formulation of the anti-seizure medication carbamazepine.
|
